GLP-1 Drug Pipeline Visual: Every Weight Loss Medication in Development (2026)
Visual map of every GLP-1 and weight loss medication currently in clinical trials, from Phase 1 through FDA approval. See what is coming next after semaglutide and tirzepatide.
More on Data Visualization
Pipeline Overview
Over a dozen weight loss medications are in clinical development. The next 2-3 years will bring oral options, triple agonists, and combination therapies. Meanwhile, semaglutide ($99/mo) and tirzepatide ($125/mo) are available now through Trimi.
Drug Pipeline Map
Retatrutide (Eli Lilly)
Triple: GLP-1/GIP/Glucagon
weight loss
Orforglipron (Eli Lilly)
Oral GLP-1 agonist
weight loss
Survodutide (Boehringer)
Dual: GLP-1/Glucagon
weight loss
CagriSema (Novo Nordisk)
Semaglutide + Cagrilintide
weight loss
Amycretin (Novo Nordisk)
Oral: GLP-1/Amylin
weight loss
Pemvidutide (Altimmune)
Dual: GLP-1/Glucagon
weight loss
Pipeline data as of April 2026. Approval timelines are estimates and subject to change based on trial results and FDA review.
Available Now at Trimi
Semaglutide
$99/mo
FDA-approved. Available now.
Tirzepatide
$125/mo
FDA-approved. Available now.
Retatrutide
Ask us
Compounded. Ask about availability.
Medical Disclaimer: Pipeline drugs are investigational and not yet FDA-approved for weight loss. This information is for educational purposes. Consult your provider about currently available options.
Frequently Asked Questions
What weight loss drugs are coming after Wegovy and Mounjaro?
Several next-generation drugs are in development: retatrutide (triple agonist, Phase 3), orforglipron (oral GLP-1, Phase 3), amycretin (oral dual agonist, Phase 2), survodutide (dual agonist, Phase 3), and CagriSema (combination, Phase 3). Multiple oral options are expected by 2027-2028.
When will retatrutide be FDA approved?
Retatrutide is in Phase 3 trials (TRIUMPH program) with results expected in 2026-2027. If successful, FDA approval could come in late 2027 or 2028. Compounded versions may be available sooner through providers like Trimi.
Will oral GLP-1 pills replace injections?
Oral options like orforglipron and amycretin are showing promising results. While convenience is higher, early data suggests injectable forms may still produce slightly higher weight loss. Both forms will likely coexist to serve different patient preferences.
Which pipeline drug looks most promising?
Retatrutide has shown the highest weight loss in trials to date (24%+ at 48 weeks). Amycretin is notable as an oral medication matching injectable GLP-1 efficacy. CagriSema combines two proven compounds for potentially enhanced results.
Why Wait? Start Treatment Today
Compounded semaglutide from $99/mo or tirzepatide from $125/mo.
View Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).